Skip to main content
UniHealth

Doctor search

Sharon J Sha, MD

Neuropsychiatry · Stanford

NPI 1225299027

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sha’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A104145 · Current

Licensed to practise in California · since 2008 · expires 2028-03-31 · Georgetown University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Community Hospital of the Monterey Peninsula

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Community Hospital of the Monterey Peninsula
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.48 (1.22 to 1.74)WorseJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths3.12 (1.69 to 4.56) · 1,095 casesWorseJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths19.24 (14.17 to 24.3) · 1,118 casesWorseJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths9.62 (6.42 to 12.82) · 1,086 casesWorseJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.39BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.27 (0.39 to 2.16) · 1,873 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths158.2 (110.65 to 205.75) · 140 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.3 · 74 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.8 · 135 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 184 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.7 · 686 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.4 · 1,072 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8 · 328 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.8 · 3,300 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.29 (0.11 to 0.48) · 10,234 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.1 to 0.46) · 10,572 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.25 (1.47 to 5.04) · 2,617 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.37 (1.04 to 3.7) · 2,519 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.21 (0.75 to 3.66) · 744 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.61 (0.06 to 1.17) · 8,715 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths5.2 · 156 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.28No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.799No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.732No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.7 · 152 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.6 · 625 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits6.3 · 193 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.2 · 749 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7 · 1,074 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.5 · 850 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4 (2.7 to 5.8) · 224 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.5 (10.4 to 17.4) · 224 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 153 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.5 · 49 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.2 (10.9 to 18.6) · 711 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (1 to 1.5) · 746 casesNo differentJan 2024 – Dec 2024

What patients said (520 patients answered, 28% of those asked)

Patient survey stars by topic at Community Hospital of the Monterey Peninsula
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating5
Quietness3
Recommend hospital5
Share of patients giving the best answer at Community Hospital of the Monterey Peninsula
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect89%
Patients who gave a rating of "9" or "10" (high)82%
Staff "always" explained new medications79%
Nurses "always" explained things so they could understand79%
Nurses "always" listened carefully77%
Nurses "always" treated them with courtesy and respect89%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital84%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$27,923

Medicare paid this office $27,923 for 182 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)130$16,836$115
Long return visit (40+ min)32$5,416$155
New patient visit (60+ min)33$4,825$146
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or11$282$24

Who their Medicare patients are

182 Original Medicare patients in 2024. Average age 78 · Women 52% · Also on Medicaid 15% · Health risk score 1.36. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 1.55.

Conditions among them: Dementia 65% · High blood pressure 62% · Depression 35% · Coronary heart disease 28% · Diabetes 22% · Chronic kidney disease 18% · Cancer 16% · Atrial fibrillation 15% · Stroke 15% · Heart failure 13% · COPD 10%.

The office billed $76,231, Medicare allowed $39,565 and paid $27,923; for 235 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024182235781.36$76,231$27,923
2023182217781.29$86,528$24,756
2022229330781.35$165,946$38,519
2021224286791.39$179,970$33,650
2020241343781.27$194,759$32,493
2019234329781.14$53,501$32,759
2018248344781.14$55,584$34,363
2017264363771.27$99,209$35,708
2016332489761.27$161,467$47,157
2015372634761.19$199,634$61,431
2014225495751.17$148,428$47,152
2013114192741.05$71,461$20,207

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Long return visit (40+ min)154$19,868$112
New patient visit (60+ min)34$4,739$139

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)178$26,200$111
New patient visit (60+ min)77$11,435$149
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or11$354$25

2021: 3 services

Original Medicare services billed in 2021
Long return visit (40+ min)171$23,902$117
New patient visit (60+ min)55$8,491$154
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or13$599$30

2020: 6 services

Original Medicare services billed in 2020
Long return visit (40+ min)161$17,993$94
New patient visit (60+ min)54$7,130$132
Long return visit (40+ min)26$2,635$98
Telephone medical discussion with physician, 21-30 minutes17$1,250$74
Return visit (30+ min)20$810$40
Telehealth originating site facility fee11$217$20

2019: 3 services

Original Medicare services billed in 2019
Long return visit (40+ min)178$20,442$90
New patient visit (60+ min)74$9,669$131
Extended office or other outpatient service, first hour17$1,887$111

2018: 4 services

Original Medicare services billed in 2018
Long return visit (40+ min)148$14,518$83
New patient visit (60+ min)68$8,849$130
Long return visit (40+ min)60$6,085$100
New patient visit (60+ min)21$3,161$151

2017: 3 services

Original Medicare services billed in 2017
Long return visit (40+ min)189$20,583$86
New patient visit (60+ min)87$12,043$138
Extended office or other outpatient service, first hour17$2,146$107

2016: 6 services

Original Medicare services billed in 2016
Long return visit (40+ min)198$22,057$89
New patient visit (60+ min)109$14,654$134
Extended office or other outpatient service, first hour28$2,603$81
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,458$121
Return visit (30+ min)21$1,219$53
Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test15$1,052$70

2015: 5 services

Original Medicare services billed in 2015
Long return visit (40+ min)242$27,474$86
New patient visit (60+ min)168$22,930$136
Extended office or other outpatient service, first hour78$6,450$81
Return visit (30+ min)38$3,115$66
Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test11$768$70

2014: 4 services

Original Medicare services billed in 2014
Long return visit (40+ min)142$17,713$88
New patient visit (60+ min)117$16,032$137
Extended office or other outpatient service, first hour111$9,322$82
Return visit (30+ min)39$2,965$64

2013: 3 services

Original Medicare services billed in 2013
New patient visit (60+ min)75$10,465$140
Long return visit (40+ min)47$5,636$92
Extended office or other outpatient service, first hour31$2,684$79

Drugs they prescribed that Part D paid

$273,987

Pharmacies billed $273,987 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 686) in 2024. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 0%.

630 generic and 56 brand-name prescriptions · $273,987 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Austedo19$230,236$12,118
Rivastigmine77$13,366$174
Memantine35$3,836$110
Donepezil207$2,936$14
Rivastigmine33$2,258$68
See all 10 drugs
Every Part D drug this clinician prescribed
Austedo19$230,236$12,118
Rivastigmine77$13,366$174
Memantine35$3,836$110
Donepezil207$2,936$14
Rivastigmine33$2,258$68
Sertraline150$724$5
Mirtazapine44$544$12
Escitalopram48$507$11
Donepezil Hcl Odt20$326$16
Risperidone11$56$5

Year by year

Part D prescribing by year
20246861320% (0)8%$273,987
20236351210% (0)5%$199,054
20225261200% (0)5%$56,463
20214691030% (0)7%$43,306
20205951090% (0)9%$51,259
20196671190% (0)7%$57,741
20186911230% (0)8%$84,682
20177071200% (0)11%$139,621
20167441100% (0)8%$42,839
20156831170% (0)14%$39,971
2014387680% (0)17%$25,592
201399290% (0)31%$13,478

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Part D drugs prescribed in 2023
Rivastigmine42$12,599$300
Donepezil255$4,686$18
Rivastigmine28$2,861$102
Memantine Hcl Er12$2,764$230
Memantine26$2,190$84
Sertraline134$1,039$8
Mirtazapine38$824$22
Escitalopram31$592$19

2022: 9 drugs

Part D drugs prescribed in 2022
Rivastigmine27$3,504$130
Donepezil219$3,450$16
Rivastigmine26$1,778$68
Sertraline110$1,023$9
Memantine31$723$23
Mirtazapine22$603$27
Carbidopa-Levodopa13$386$30
Escitalopram20$382$19
Quetiapine13$278$21

2021: 8 drugs

Part D drugs prescribed in 2021
Rivastigmine46$9,909$215
Donepezil158$3,078$19
Sertraline100$1,266$13
Carbidopa-Levodopa17$851$50
Memantine22$802$36
Rivastigmine13$789$61
Escitalopram31$536$17
Mirtazapine16$527$33

2020: 10 drugs

Part D drugs prescribed in 2020
Rivastigmine53$14,932$282
Exelon13$14,908$1,147
Tetrabenazine11$7,691$699
Donepezil192$3,456$18
Rivastigmine31$2,073$67
Citalopram Hbr12$1,079$90
Sertraline122$1,066$9
Mirtazapine26$928$36
Escitalopram62$708$11
Memantine23$648$28

2019: 12 drugs

Part D drugs prescribed in 2019
Rivastigmine42$14,719$350
Memantine Hcl Er21$5,927$282
Donepezil236$3,597$15
Citalopram Hbr27$2,233$83
Rivastigmine20$1,929$96
Mirtazapine46$1,770$38
Sertraline104$990$10
Escitalopram68$881$13
Memantine19$527$28
Quetiapine14$244$17
Carbidopa-Levodopa13$242$19
Trazodone12$115$10

2018: 13 drugs

Part D drugs prescribed in 2018
Tetrabenazine12$27,625$2,302
Rivastigmine46$20,753$451
Exelon17$16,268$957
Donepezil250$3,469$14
Memantine Hcl Er16$3,352$210
Rivastigmine26$2,781$107
Citalopram Hbr34$1,366$40
Sertraline101$1,266$13
Mirtazapine38$1,034$27
Escitalopram50$693$14
Quetiapine17$206$12
Trazodone16$188$12
Clonazepam12$68$6

2017: 14 drugs

Part D drugs prescribed in 2017
Exelon24$21,513$896
Rivastigmine55$20,889$380
Namenda Xr15$6,770$451
Donepezil250$3,520$14
Rivastigmine30$2,610$87
Mirtazapine32$1,946$61
Memantine25$1,318$53
Sertraline63$719$11
Escitalopram44$480$11
Quetiapine39$369$9
Carbidopa-Levodopa15$321$21
Trazodone27$234$9
Citalopram Hbr40$213$5
Clonazepam11$68$6

2016: 11 drugs

Part D drugs prescribed in 2016
Exelon19$14,397$758
Namenda Xr15$6,833$456
Rivastigmine26$6,249$240
Donepezil373$4,601$12
Mirtazapine31$2,763$89
Memantine26$2,033$78
Quetiapine45$1,065$24
Escitalopram49$453$9
Sertraline23$364$16
Citalopram Hbr70$360$5
Trazodone34$220$6

2015: 10 drugs

Part D drugs prescribed in 2015
Exelon25$14,885$595
Namenda24$8,420$351
Namenda Xr13$6,606$508
Donepezil357$3,510$10
Citalopram Hbr100$685$7
Carbidopa-Levodopa18$580$32
Sertraline42$275$7
Escitalopram27$238$9
Trazodone28$161$6
Quetiapine11$157$14

2014: 7 drugs

Part D drugs prescribed in 2014
Exelon43$15,974$371
Namenda15$4,376$292
Donepezil201$2,271$11
Citalopram Hbr58$317$5
Trazodone23$145$6
Sertraline12$85$7
Escitalopram11$76$7

2013: 2 drugs

Part D drugs prescribed in 2013
Namenda21$6,845$326
Donepezil59$2,058$35

Money from drug and device companies

$29 in 2025

Industry payments by year
202511None$29
202422$4,680$4,746
2022213None$2,000
201944$1,020$1,303

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenentechNone$29
1 payment
  • Meals · 2025-12-02 · $29
See the published payment
Every published payment
GenentechMeals · 2025-12-02None$29
See earlier years (2024, 2022, 2019)

2024: $4,746

Payments by company in 2024
EisaiLeqembi$4,680
1 payment
  • Consulting for Leqembi · 2024-03-04 · $4,680
BiogenNone$66
1 payment
  • Meals · 2024-10-31 · $66

2022: $2,000

Payments by company in 2022
BiogenNone$1,898
12 payments
  • Meals · 2022-12-02 · $55
  • Meals · 2022-12-02 · $39
  • Travel · 2022-10-28 · $140
  • Meals · 2022-10-28 · $30
  • Meals · 2022-10-28 · $21
  • Meals · 2022-10-28 · $9
  • Travel · 2022-10-28 · $150
  • Travel · 2022-10-27 · $300
  • Travel · 2022-10-27 · $193
  • Travel · 2022-10-27 · $220
  • Meals · 2022-10-27 · $124
  • Travel · 2022-10-20 · $617
EisaiNone$103
1 payment
  • Meals · 2022-08-01 · $103

2019: $1,303

Payments by company in 2019
Genentech USAActivase$1,020
1 payment
  • Consulting for Activase · 2019-02-08 · $1,020
Medtronic USAActiva$169
1 payment
  • Meals for Activa · 2019-05-23 · $169
BiogenNone$63
1 payment
  • Meals · 2019-12-05 · $63
EisaiNone$51
1 payment
  • Meals · 2019-12-05 · $51

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2021Their institution$386,718
Novartis Pharmaceuticals Corporation · A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia · 2019Their institution$349,537
Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2022Their institution$344,819
Biogen, Inc. · 221ad302 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2019Their institution$341,775
Eisai Inc. · Ahead 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With An Extension Phase To Evaluate Efficacy and Safety of Treatment With Ban2401 in Subjects With Preclinical Alzheimer'S Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid (A3 Trial) · 2023Their institution$327,750
Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2019Their institution$311,367
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study To Evaluate Efficacy and Safety of Treatment With Ban2401 in Subjects With Preclinical Alzheimer'S Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid (A3 Trial) · 2025Their institution$306,515
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Parallel Group Study To Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad · 2019Their institution$302,681
Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2024Their institution$280,789
Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022Their institution$265,907
Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2020Their institution$253,155
Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2019Their institution$231,550
Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2023Their institution$218,333
Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023Their institution$199,406
Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2021Their institution$180,247
Novartis Pharmaceuticals Corporation · A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia · 2020Their institution$179,661
Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2021Their institution$174,571
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2024Their institution$150,050
Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2020Their institution$138,059
Genentech, Inc. · Digital in Ad Poc Study · 2021Their institution$136,612
Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2022Their institution$122,569
Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2025Their institution$119,620
Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2024Their institution$113,206
Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2023Their institution$108,944
Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2024Their institution$105,151
UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimers Disease (Ad), Followed By An Open-Label Extensio · 2022Their institution$75,707
Eisai Inc. · A Study To Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer'S Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid · 2021Their institution$72,560
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial To Study the Efficacy and Safety of Mk-8931 Sch 900931 in Subjects With Amnestic Mild Cognitive Impairment Due To Alzheimer S Disease Prodromal Ad. · 2019Their institution$64,093
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2021Their institution$50,791
Genentech, Inc. · Prodromal To Mild Ad · 2019Their institution$50,771
Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2019Their institution$41,825
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2025Their institution$39,365
Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2021Their institution$39,278
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2022Their institution$38,030
Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2020Their institution$34,651
Biogen, Inc. · 221ad302 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2020Their institution$28,583
Genentech, Inc. · Phase II Study for Moderate Ad · 2020Their institution$28,404
Genentech, Inc. · Digital in Ad Poc Study · 2022Their institution$27,680
ACADIA Pharmaceuticals Inc · Nuplazid · 2021Their institution$18,656
Genentech, Inc. · Phase II Study for Moderate Ad · 2019Their institution$18,319
Biogen, Inc. · An Observational Study Using Multimodal Sensors To Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging. · 2022This clinician$15,019
UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimer'S Disease (Ad), Followed By An Open-Label Extension Period · 2023Their institution$13,148
Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2025Their institution$11,956
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2023Their institution$11,612
ACADIA Pharmaceuticals Inc · Nuplazid · 2022Their institution$11,466
Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With An Open-Label Extension Phase To Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer'S Disease · 2020Their institution$10,948
Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2020Their institution$9,529
Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2021Their institution$9,255
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Parallel Group Study To Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad · 2020Their institution$8,799
Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2025Their institution$8,321
Genentech, Inc. · Digital in Ad Poc Study · 2023Their institution$8,136
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Karxt + Karx-Ec for the Treatment of Cognitive Impairment Associated With Mild-To-Moderate Alzheimers Disease (Mindset 2) · 2025Their institution$5,343
Eli Lilly and Company · Assessment of Safety and Efficacy of Intravenous Remternetug in Early Symptomatic Alzheimers Disease · 2025Their institution$5,314
Genentech, Inc. · Phase II Study for Moderate Ad · 2021Their institution$1,867
Genentech, Inc. · Prodromal To Mild Ad · 2021Their institution$1,551
Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2023This clinician$1,358
Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2023Their institution$664
Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023This clinician$380
Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022This clinician$300
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial To Study the Efficacy and Safety of Mk-8931 Sch 900931 in Subjects With Amnestic Mild Cognitive Impairment Due To Alzheimer S Disease Prodromal Ad. · 2021Their institution$62

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1225299027
Licence
CA A104145California A104145: Current · expires 2028-03-31
Trained
Georgetown University School of Medicine, 2006
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 2084B0040X (2084B0040X); Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2008-06-24
NPI last updated
2023-11-06
NPI record certified
2023-11-06

This is when the NPI record was last certified, not a medical board exam.